Gemlieva RTU 1000 mg contains Gemcitabine, a nucleoside analog antimetabolite chemotherapy agent. The RTU (Ready-to-Use) formulation enhances convenience and reduces preparation time in oncology settings. It is administered intravenously under medical supervision.

🔬 Mechanism of Action

Gemcitabine is incorporated into DNA during replication. As a result:

• DNA synthesis is inhibited
• Cancer cell division is disrupted
• Tumor growth slows or cancer cells undergo apoptosis

Because it targets rapidly dividing cells, it is effective across multiple solid tumors.

💊 Indications

Gemlieva RTU 1000 mg is indicated for:

• Non-Small Cell Lung Cancer (NSCLC)
• Pancreatic Cancer
• Breast Cancer
• Ovarian Cancer
• Bladder Cancer

It is often used in combination with other chemotherapy agents such as cisplatin, carboplatin, or paclitaxel.

📌 Key Features

• Strength: 1000 mg
• Dosage Form: Ready-to-Use Intravenous Injection
• Therapeutic Class: Antimetabolite Chemotherapy
• Administration: IV infusion under oncologist supervision
• Monitoring: Regular complete blood count (CBC), liver and kidney function tests required

⚕️ Benefits

• Broad-spectrum anticancer activity
• RTU formulation improves clinical efficiency
• Effective in combination regimens
• Established role in standard oncology protocols

⚠️ Precautions

• Risk of myelosuppression (anemia, neutropenia, thrombocytopenia)
• Nausea, vomiting, and fatigue may occur
• Liver and kidney function monitoring required
• Use strictly under oncologist supervision

Gemlieva RTU 1000 mg (Gemcitabine Injection) is a widely used and effective chemotherapy agent in modern cancer treatment, offering reliable tumor control and clinical convenience when administered under specialized oncology care.